Cargando…

Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis

This study aims to provide practical recommendations on prophylaxis for infection in pediatric patients with immune-mediated rheumatic diseases receiving/scheduled to receive immunosuppressive therapy. A qualitative approach was applied. A narrative literature review was performed via Medline. Prima...

Descripción completa

Detalles Bibliográficos
Autores principales: Clemente Garulo, Daniel, Núñez-Cuadros, Esmeralda, Camacho Lovillo, Marisol, Calzada-Hernández, Joan, Guillén Martín, Sara, Fernández Silveira, Laura, Lirola Cruz, María José, Tagarro, Alfredo, Alcobendas Rueda, Rosa María, López López, Agustín, Satrustegi Aritziturri, Miren, Calvo, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570166/
https://www.ncbi.nlm.nih.gov/pubmed/37439850
http://dx.doi.org/10.1007/s00431-023-05080-3
_version_ 1785119702150807552
author Clemente Garulo, Daniel
Núñez-Cuadros, Esmeralda
Camacho Lovillo, Marisol
Calzada-Hernández, Joan
Guillén Martín, Sara
Fernández Silveira, Laura
Lirola Cruz, María José
Tagarro, Alfredo
Alcobendas Rueda, Rosa María
López López, Agustín
Satrustegi Aritziturri, Miren
Calvo, Cristina
author_facet Clemente Garulo, Daniel
Núñez-Cuadros, Esmeralda
Camacho Lovillo, Marisol
Calzada-Hernández, Joan
Guillén Martín, Sara
Fernández Silveira, Laura
Lirola Cruz, María José
Tagarro, Alfredo
Alcobendas Rueda, Rosa María
López López, Agustín
Satrustegi Aritziturri, Miren
Calvo, Cristina
author_sort Clemente Garulo, Daniel
collection PubMed
description This study aims to provide practical recommendations on prophylaxis for infection in pediatric patients with immune-mediated rheumatic diseases receiving/scheduled to receive immunosuppressive therapy. A qualitative approach was applied. A narrative literature review was performed via Medline. Primary searches were conducted using MeSH terms and free text to identify articles that analyzed data on infections and vaccinations in pediatric patients with immune-mediated rheumatic diseases receiving immunosuppressive therapy. The results were presented and discussed in a nominal group meeting comprising a committee of 12 pediatric rheumatologists from the Prevention and Treatment of Infections Working Group of the Spanish Society of Pediatric Rheumatology. Several recommendations were generated. A consensus procedure was implemented via a Delphi process that was extended to members of the Spanish Society of Pediatric Rheumatology and the Vaccine Advisory Committee of the Spanish Association of Pediatrics. Participants produced a score ranging from 0 (completely disagree) to 10 (completely agree). Agreement was considered to have been reached if at least 70% of participants voted ≥ 7. The literature review included more than 400 articles. Overall, 63 recommendations were generated (23 on infection prophylaxis) and voted by 59 pediatric rheumatologists and other pediatric specialists, all of whom achieved the pre-established level of agreement. The recommendations on prophylaxis of infection cover vaccination and prophylaxis against varicella zoster virus, tuberculosis, Pneumocystis jiroveccii, and invasive fungal infections in pediatric patients with immune-mediated rheumatic diseases receiving/scheduled to receive immunosuppressive therapy.   Conclusion: Based on current evidence and a Delphi process, we provided consensus and updated recommendations on prophylaxis and treatment of infections to guide those caring for pediatric rheumatology patients.
format Online
Article
Text
id pubmed-10570166
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-105701662023-10-14 Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis Clemente Garulo, Daniel Núñez-Cuadros, Esmeralda Camacho Lovillo, Marisol Calzada-Hernández, Joan Guillén Martín, Sara Fernández Silveira, Laura Lirola Cruz, María José Tagarro, Alfredo Alcobendas Rueda, Rosa María López López, Agustín Satrustegi Aritziturri, Miren Calvo, Cristina Eur J Pediatr Guideline This study aims to provide practical recommendations on prophylaxis for infection in pediatric patients with immune-mediated rheumatic diseases receiving/scheduled to receive immunosuppressive therapy. A qualitative approach was applied. A narrative literature review was performed via Medline. Primary searches were conducted using MeSH terms and free text to identify articles that analyzed data on infections and vaccinations in pediatric patients with immune-mediated rheumatic diseases receiving immunosuppressive therapy. The results were presented and discussed in a nominal group meeting comprising a committee of 12 pediatric rheumatologists from the Prevention and Treatment of Infections Working Group of the Spanish Society of Pediatric Rheumatology. Several recommendations were generated. A consensus procedure was implemented via a Delphi process that was extended to members of the Spanish Society of Pediatric Rheumatology and the Vaccine Advisory Committee of the Spanish Association of Pediatrics. Participants produced a score ranging from 0 (completely disagree) to 10 (completely agree). Agreement was considered to have been reached if at least 70% of participants voted ≥ 7. The literature review included more than 400 articles. Overall, 63 recommendations were generated (23 on infection prophylaxis) and voted by 59 pediatric rheumatologists and other pediatric specialists, all of whom achieved the pre-established level of agreement. The recommendations on prophylaxis of infection cover vaccination and prophylaxis against varicella zoster virus, tuberculosis, Pneumocystis jiroveccii, and invasive fungal infections in pediatric patients with immune-mediated rheumatic diseases receiving/scheduled to receive immunosuppressive therapy.   Conclusion: Based on current evidence and a Delphi process, we provided consensus and updated recommendations on prophylaxis and treatment of infections to guide those caring for pediatric rheumatology patients. Springer Berlin Heidelberg 2023-07-13 2023 /pmc/articles/PMC10570166/ /pubmed/37439850 http://dx.doi.org/10.1007/s00431-023-05080-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Guideline
Clemente Garulo, Daniel
Núñez-Cuadros, Esmeralda
Camacho Lovillo, Marisol
Calzada-Hernández, Joan
Guillén Martín, Sara
Fernández Silveira, Laura
Lirola Cruz, María José
Tagarro, Alfredo
Alcobendas Rueda, Rosa María
López López, Agustín
Satrustegi Aritziturri, Miren
Calvo, Cristina
Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis
title Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis
title_full Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis
title_fullStr Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis
title_full_unstemmed Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis
title_short Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis
title_sort position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis
topic Guideline
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570166/
https://www.ncbi.nlm.nih.gov/pubmed/37439850
http://dx.doi.org/10.1007/s00431-023-05080-3
work_keys_str_mv AT clementegarulodaniel positionstatementoninfectionscreeningprophylaxisandvaccinationinpediatricpatientswithrheumaticdiseasesandimmunosuppressivetherapiespart2infectionprophylaxis
AT nunezcuadrosesmeralda positionstatementoninfectionscreeningprophylaxisandvaccinationinpediatricpatientswithrheumaticdiseasesandimmunosuppressivetherapiespart2infectionprophylaxis
AT camacholovillomarisol positionstatementoninfectionscreeningprophylaxisandvaccinationinpediatricpatientswithrheumaticdiseasesandimmunosuppressivetherapiespart2infectionprophylaxis
AT calzadahernandezjoan positionstatementoninfectionscreeningprophylaxisandvaccinationinpediatricpatientswithrheumaticdiseasesandimmunosuppressivetherapiespart2infectionprophylaxis
AT guillenmartinsara positionstatementoninfectionscreeningprophylaxisandvaccinationinpediatricpatientswithrheumaticdiseasesandimmunosuppressivetherapiespart2infectionprophylaxis
AT fernandezsilveiralaura positionstatementoninfectionscreeningprophylaxisandvaccinationinpediatricpatientswithrheumaticdiseasesandimmunosuppressivetherapiespart2infectionprophylaxis
AT lirolacruzmariajose positionstatementoninfectionscreeningprophylaxisandvaccinationinpediatricpatientswithrheumaticdiseasesandimmunosuppressivetherapiespart2infectionprophylaxis
AT tagarroalfredo positionstatementoninfectionscreeningprophylaxisandvaccinationinpediatricpatientswithrheumaticdiseasesandimmunosuppressivetherapiespart2infectionprophylaxis
AT alcobendasruedarosamaria positionstatementoninfectionscreeningprophylaxisandvaccinationinpediatricpatientswithrheumaticdiseasesandimmunosuppressivetherapiespart2infectionprophylaxis
AT lopezlopezagustin positionstatementoninfectionscreeningprophylaxisandvaccinationinpediatricpatientswithrheumaticdiseasesandimmunosuppressivetherapiespart2infectionprophylaxis
AT satrustegiaritziturrimiren positionstatementoninfectionscreeningprophylaxisandvaccinationinpediatricpatientswithrheumaticdiseasesandimmunosuppressivetherapiespart2infectionprophylaxis
AT calvocristina positionstatementoninfectionscreeningprophylaxisandvaccinationinpediatricpatientswithrheumaticdiseasesandimmunosuppressivetherapiespart2infectionprophylaxis